Oxford BioMedica PLC to Present at Conference

Published: Aug 29, 2012

OXFORD, UNITED KINGDOM--(Marketwire - August 29, 2012) -

Oxford BioMedica to Present at the 2012 Rodman & Renshaw Annual Global
Investment Conference

-- 14th Annual Healthcare Conference --

Oxford, UK - 29 August 2012: Oxford BioMedica plc ("Oxford BioMedica"
or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical
company, today announces that John Dawson, Chief Executive Officer of
Oxford BioMedica, will present at the Rodman & Renshaw Annual Global
Investment Conference to be held on September 9-11, 2012 at The Waldorf
Astoria, NY (USA).

The presentation is scheduled for Monday, 10 September 2012 at 16:30
Eastern Time. A copy of the slide presentation will be made available
on the "Investors/Corporate presentations" section of the Company's
website at www.oxfordbiomedica.co.uk.


For further information, please contact:

Oxford BioMedica plc:                              Tel: +44 (0)1865 783
Lara Mott, Head of Corporate Communications

Media Enquiries:                                   Tel: +44 (0)20 7920
Mary Clark/Sarah Macleod/Claire Dickinson

Notes to editors

1. Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company
developing innovative gene-based medicines and therapeutic vaccines
that aim to improve the lives of patients with high unmet medical
needs. The Company's technology platform includes a highly efficient
LentiVector® gene delivery system, which has specific advantages for
targeting diseases of the central nervous system and the eye; and a
unique tumour antigen (5T4), which is an ideal target for anti-cancer
therapy. Through in-house and collaborative research, Oxford BioMedica
has a broad pipeline with current partners and licensees including
Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec,
Emergent BioSolutions and ImaginAb. Further information is available
at www.oxfordbiomedica.co.uk.

                    This information is provided by RNS
          The company news service from the London Stock Exchange


Email Contact

Back to news